Review On Cervical Cancer, Associate Risk, Staging, Screening Tests, Therapies and Vaccination
Year: 2024
Type: article
Abstract: Over 300,000 people die from cervical cancer worldwide, making it the fourth most frequent malignancy among women. Prolonged infection with high-risk subtypes of the human papillomavirus is the cause of cervical cancer, and the E5, E6, and E7 viral oncoproteins work in tandem with host factors to initiate and sustain the malignant phenotype. The majority of cervical cancer may be prevented, and survival rates are considerably higher when the disease is detected early. It is considered a rare disease in high-income nations with well-established screening and vaccination programs. But in low- and middle-income nations, where resources are scarce, the disease kills women, who frequently have advanced, incurable sickness. Surgical procedures, chemotherapy, and/or radiation therapy are available as treatments, either separately or in combination.
Author: Shweta Gadekar*, Tejaswini Bhadake, Dr. Gajanan Sanap
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6949521565